Skip to main content
Clinical Trials/NCT05966675
NCT05966675
Recruiting
N/A

Physiologic Cardiac Pacing to Prevent Left Ventricular Dysfunction Post Transcatheter Aortic Valve Implantation

Medical University of Silesia1 site in 1 country500 target enrollmentFebruary 27, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Atrioventricular Block, Second and Third Degree
Sponsor
Medical University of Silesia
Enrollment
500
Locations
1
Primary Endpoint
Heart Failure Hospitalization
Status
Recruiting
Last Updated
10 months ago

Overview

Brief Summary

The study aims to compare permanent Conduction System Pacing (CSP) with the standard therapy - Right Ventricular Pacing (RVP) or Biventricular Pacing (BVP) - in preventing the development and progression of symptomatic Chronic Heart Failure (CHF) and improving survival in patients after Transcatheter Aortic Valve Implantation (TAVI).

Detailed Description

A multicenter randomized controlled head-to-head trial was planned to compare the effects of permanent pacemaker implantation (PPMI) using CSP (study intervention) with currently standard therapy - RVP or BVP (control group). The study population will consist of patients hospitalized after TAVI complicated with high-degree persistent atrioventricular (AV) block or newly developed complex AV or intraventricular conduction disturbances, qualified for PPMI within 30 days after surgery, following the 2021 European Society of Cardiology (ESC) guidelines on cardiac pacing and cardiac resynchronization therapy.

Registry
clinicaltrials.gov
Start Date
February 27, 2024
End Date
June 2028
Last Updated
10 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • transcatheter aortic valve implantation (TAVI) in up to 30 days before qualification to pacemaker implantation
  • Fulfilled criteria for permanent pacemaker implantation according do 2021 ESC guidelines
  • Written informed consent
  • Age of at least 18 years

Exclusion Criteria

  • Permanent pacemaker implantation before TAVI procedure
  • The occurrence of conduction disturbances more than 30 days after TAVI procedure
  • No written informed consent
  • Inability to obtain informed consent from participant
  • Predicted inability to obtain cooperation from patient during observation period

Outcomes

Primary Outcomes

Heart Failure Hospitalization

Time Frame: 12 months

Hospitalization due to heart failure as a main reason

All-cause death

Time Frame: 12 months

Death from any cause

Secondary Outcomes

  • Pacing-Induced Cardiomyopathy (PICM)(24 months)
  • Change in global longitudinal strain (GLS)(24 months)
  • Change in the concentration of the N-terminal pro-brain natriuretic peptide (NT-proBNP)(24 months)
  • Change in Quality of Life(24 months)
  • Atrial Fibrillation (AF) episodes(24 months)
  • Change in exercise capacity(24 months)
  • Response to Cardiac Resynchronization Therapy (CRT)(24 months)
  • Atrial High Rate Episodes (AHRE) in pacemaker recordings(24 months)

Study Sites (1)

Loading locations...

Similar Trials